Allele-Specific Loss Of The Mir-15a/16-1 Cluster »
04/27/14

CD62L Expression Is Associated With »
04/27/14

Mutational and Cytogenetic Analyses »
04/27/14

Differential Distribution Of Recurrent Gene Mutations »
04/27/14

The SpiegelmerA® Nox-A12 »
04/27/14

Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) »
04/27/14

P53 Functional Assessment »
04/27/14

Serum Levels Of CD178 (Soluble FasL) Predict Treatment Response and Survival In Chronic Lymphocytic Leukaemia (CLL) »
05/02/14

The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance) »
05/02/14

Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIRTM Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) »
05/02/14